Genetically Modified Dendritic Cells in Cancer Immunotherapy

2009 ◽  
pp. 347-363 ◽  
Author(s):  
Brian J. Morrison ◽  
Jason C. Steel ◽  
Melissa Gregory ◽  
John C. Morris ◽  
Anatoli M. Malyguine
Keyword(s):  
Dendritic Cells ◽  
Cancer Immunotherapy ◽  
Genetically Modified

Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?

2010 ◽  
Vol 10 (11) ◽  
pp. 1539-1553 ◽  
Author(s):  
Michael R Shurin ◽  
Melissa Gregory ◽  
John C Morris ◽  
Anatoli M Malyguine
Keyword(s):  
Dendritic Cells ◽  
Cancer Immunotherapy ◽  
Genetically Modified

scholarly journals Cancer Immunotherapy Using In vitro Genetically Modified Targeted Dendritic Cells

2008 ◽  
Vol 68 (10) ◽  
pp. 3854-3862 ◽  
Author(s):  
Huafeng Wei ◽  
Hao Wang ◽  
Bing Lu ◽  
Bohua Li ◽  
Sheng Hou ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Cancer Immunotherapy ◽  
Genetically Modified

scholarly journals Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells

2015 ◽  
Vol 6 (1) ◽  
pp. 71-79 ◽  
Author(s):  
Alfonso R. Sánchez-Paulete ◽  
Francisco J. Cueto ◽  
María Martínez-López ◽  
Sara Labiano ◽  
Aizea Morales-Kastresana ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Monoclonal Antibodies ◽  
Cancer Immunotherapy

Antigen delivery to dendritic cells: Implications for cancer immunotherapy

1999 ◽  
Vol 19 (10-11) ◽  
pp. 131-135
Author(s):  
Jayakar V. Nayak ◽  
Louis D. Falo
Keyword(s):  
Dendritic Cells ◽  
Cancer Immunotherapy ◽  
Antigen Delivery

scholarly journals Induction of Potent Human Immunodeficiency Virus Type 1-Specific T-Cell-Restricted Immunity by Genetically Modified Dendritic Cells

2001 ◽  
Vol 75 (16) ◽  
pp. 7621-7628 ◽  
Author(s):  
Julianna Lisziewicz ◽  
Dmitry I. Gabrilovich ◽  
Georg Varga ◽  
Jianqing Xu ◽  
Philip D. Greenberg ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Dendritic Cells ◽  
T Cell ◽  
Human Immunodeficiency Virus Type ◽  
Plasmid Dna ◽  
Genetically Modified ◽  
Ctl Response ◽  
Immunodeficiency Virus ◽  
Hiv 1

ABSTRACT A novel technology combining replication- and integration-defective human immunodeficiency virus type 1 (HIV-1) vectors with genetically modified dendritic cells was developed in order to induce T-cell immunity. We introduced the vector into dendritic cells as a plasmid DNA using polyethylenimine as the gene delivery system, thereby circumventing the problem of obtaining viral vector expression in the absence of integration. Genetically modified dendritic cells (GMDC) presented viral epitopes efficiently, secreted interleukin 12, and primed both CD4+ and CD8+ HIV-specific T cells capable of producing gamma interferon and exerting potent HIV-1-specific cytotoxicity in vitro. In nonhuman primates, subcutaneously injected GMDC migrated into the draining lymph node at an unprecedentedly high rate and expressed the plasmid DNA. The animals presented a vigorous HIV-specific effector cytotoxic-T-lymphocyte (CTL) response as early as 3 weeks after a single immunization, which later developed into a memory CTL response. Interestingly, antibodies did not accompany these CTL responses, indicating that GMDC can induce a pure Th1 type of immune response. Successful induction of a broad and long-lasting HIV-specific cellular immunity is expected to control virus replication in infected individuals.

Sign in / Sign up

Export Citation Format

Share Document